<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Frutiger-UltraBlack,Bold" color="#4e67ad"/>
	<fontspec id="font1" size="9" family="Frutiger-UltraBlack,Bold" color="#007682"/>
	<fontspec id="font2" size="9" family="Courier" color="#007682"/>
	<fontspec id="font3" size="9" family="Frutiger-Light" color="#000000"/>
	<fontspec id="font4" size="9" family="Arial" color="#000000"/>
	<fontspec id="font5" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font6" size="24" family="Frutiger-UltraBlack,Bold" color="#000000"/>
	<fontspec id="font7" size="11" family="Helvetica-Black,Bold" color="#ffffff"/>
	<fontspec id="font8" size="14" family="GillSans-Light" color="#000000"/>
	<fontspec id="font9" size="16" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font10" size="15" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font11" size="11" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font12" size="8" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font13" size="6" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font14" size="11" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font15" size="10" family="GillSans" color="#000000"/>
	<fontspec id="font16" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font17" size="10" family="Giovanni-BookItalic,Italic" color="#000000"/>
	<fontspec id="font18" size="7" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font19" size="9" family="GillSans,BoldItalic" color="#000000"/>
	<fontspec id="font20" size="8" family="GillSans" color="#000000"/>
	<fontspec id="font21" size="8" family="GillSans,Italic" color="#000000"/>
	<fontspec id="font22" size="8" family="GillSans,Bold" color="#000000"/>
<text top="44" left="508" width="67" height="9" font="font0" id="p1_t1" reading_order_no="1" segment_no="1" tag_type="title">Bio Med Central<a href="http://www.biomedcentral.com/"><b>Bio</b></a></text>
<text top="756" left="508" width="46" height="10" font="font4" id="p1_t2" reading_order_no="67" segment_no="22" tag_type="text">Page 1 of 9<a href="http://www.biomedcentral.com/"><b>Med</b></a></text>
<text top="769" left="432" width="122" height="8" font="font5" id="p1_t3" reading_order_no="68" segment_no="23" tag_type="text">(page number not for citation purposes)<a href="http://www.biomedcentral.com/">Central</a></text>
<text top="35" left="55" width="397" height="23" font="font6" id="p1_t4" reading_order_no="0" segment_no="0" tag_type="title">Genetic Vaccines and Therapy</text>
<text top="86" left="502" width="79" height="10" font="font7" id="p1_t5" reading_order_no="2" segment_no="2" tag_type="title">Open Access<i>(page number not for citation purposes)</i></text>
<text top="87" left="55" width="40" height="13" font="font8" id="p1_t6" reading_order_no="3" segment_no="3" tag_type="title">Review<b>Genetic Vaccines and Therapy</b></text>
<text top="105" left="55" width="462" height="15" font="font9" id="p1_t7" reading_order_no="4" segment_no="4" tag_type="title">Is gene therapy a good therapeutic approach for HIV-positive<a href="http://www.biomedcentral.com/info/about/charter/"><b>Open Access</b></a></text>
<text top="123" left="55" width="66" height="15" font="font9" id="p1_t8" reading_order_no="5" segment_no="4" tag_type="title">patients?</text>
<text top="140" left="55" width="255" height="14" font="font10" id="p1_t9" reading_order_no="6" segment_no="5" tag_type="text">Jai G Marathe 1 and Dawn P Wooley* 1,2<b>Is gene therapy a good therapeutic approach for HIV-positive </b></text>
<text top="175" left="55" width="499" height="9" font="font12" id="p1_t10" reading_order_no="7" segment_no="6" tag_type="text">Address: 1 Department of Neuroscience, Cell Biology, and Physiology, Wright State University, Dayton, OH 45435, USA and 2 Center for Retrovirus<b>patients?</b></text>
<text top="185" left="55" width="225" height="8" font="font12" id="p1_t11" reading_order_no="8" segment_no="6" tag_type="text">Research, The Ohio State University, Columbus, OH 43210, USA</text>
<text top="200" left="55" width="321" height="8" font="font12" id="p1_t12" reading_order_no="9" segment_no="7" tag_type="text">Email: Jai G Marathe - marathe.3@wright.edu; Dawn P Wooley* - dawn.wooley@wright.edu</text>
<text top="211" left="55" width="92" height="8" font="font12" id="p1_t13" reading_order_no="10" segment_no="8" tag_type="text">* Corresponding author</text>
<text top="359" left="112" width="44" height="10" font="font14" id="p1_t14" reading_order_no="20" segment_no="16" tag_type="title">Abstract</text>
<text top="374" left="112" width="386" height="9" font="font15" id="p1_t15" reading_order_no="21" segment_no="17" tag_type="text">Despite advances and options available in gene therapy for HIV-1 infection, its application in the</text>
<text top="386" left="112" width="386" height="9" font="font15" id="p1_t16" reading_order_no="22" segment_no="17" tag_type="text">clinical setting has been challenging. Although published data from HIV-1 clinical trials show safety</text>
<text top="398" left="112" width="385" height="9" font="font15" id="p1_t17" reading_order_no="23" segment_no="17" tag_type="text">and proof of principle for gene therapy, positive clinical outcomes for infected patients have yet to</text>
<text top="409" left="112" width="386" height="9" font="font15" id="p1_t18" reading_order_no="24" segment_no="17" tag_type="text">be demonstrated. The cause for this slow progress may arise from the fact that HIV is a complex</text>
<text top="421" left="112" width="386" height="9" font="font15" id="p1_t19" reading_order_no="25" segment_no="17" tag_type="text">multi-organ system infection. There is uncertainty regarding the types of cells to target by gene</text>
<text top="433" left="112" width="386" height="9" font="font15" id="p1_t20" reading_order_no="26" segment_no="17" tag_type="text">therapy and there are issues regarding insufficient transduction of cells and long-term expression.</text>
<text top="445" left="112" width="385" height="9" font="font15" id="p1_t21" reading_order_no="27" segment_no="17" tag_type="text">This paper discusses state-of-the-art molecular approaches against HIV-1 and the application of</text>
<text top="456" left="112" width="212" height="9" font="font15" id="p1_t22" reading_order_no="28" segment_no="17" tag_type="text">these treatments in current and ongoing clinical trials.<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17300725">  </a></text>
<text top="506" left="55" width="60" height="10" font="font14" id="p1_t23" reading_order_no="29" segment_no="18" tag_type="title">Background<b>Abstract</b></text>
<text top="517" left="55" width="241" height="9" font="font16" id="p1_t24" reading_order_no="30" segment_no="20" tag_type="text">In 1983, a new virus was first isolated and associated with</text>
<text top="529" left="55" width="241" height="9" font="font16" id="p1_t25" reading_order_no="31" segment_no="20" tag_type="text">acquired immune deficiency syndrome (AIDS) [1]. Subse-</text>
<text top="541" left="55" width="241" height="9" font="font16" id="p1_t26" reading_order_no="32" segment_no="20" tag_type="text">quently, scientists classified it as a Lentivirus belonging to</text>
<text top="553" left="55" width="241" height="9" font="font16" id="p1_t27" reading_order_no="33" segment_no="20" tag_type="text">the family Retroviridae and named it human immunodefi-</text>
<text top="564" left="55" width="241" height="9" font="font16" id="p1_t28" reading_order_no="34" segment_no="20" tag_type="text">ciency virus (HIV) [2]. HIV infection not only causes phys-</text>
<text top="576" left="55" width="241" height="9" font="font16" id="p1_t29" reading_order_no="35" segment_no="20" tag_type="text">ical debility but also has negative social implications [3-</text>
<text top="588" left="55" width="241" height="9" font="font16" id="p1_t30" reading_order_no="36" segment_no="20" tag_type="text">7]. During the later stages of HIV infection, patients</text>
<text top="599" left="55" width="241" height="9" font="font16" id="p1_t31" reading_order_no="37" segment_no="20" tag_type="text">develop AIDS, presenting with severely depleted CD4 + T-</text>
<text top="611" left="55" width="241" height="9" font="font16" id="p1_t32" reading_order_no="38" segment_no="20" tag_type="text">cell counts (&lt;200 cells per microliter of blood) along with<b>Background</b></text>
<text top="623" left="55" width="241" height="9" font="font16" id="p1_t33" reading_order_no="39" segment_no="20" tag_type="text">a myriad of opportunistic infections. According to the</text>
<text top="635" left="55" width="241" height="9" font="font16" id="p1_t34" reading_order_no="40" segment_no="20" tag_type="text">Joint United Nations Programme on HIV/AIDS, approxi-<a href="">rome (AIDS) [1]. Subse-</a></text>
<text top="647" left="55" width="241" height="9" font="font16" id="p1_t35" reading_order_no="41" segment_no="20" tag_type="text">mately 30 million people have lost their lives since the</text>
<text top="658" left="55" width="241" height="9" font="font16" id="p1_t36" reading_order_no="42" segment_no="20" tag_type="text">identification of the first AIDS patients in 1980. The glo-<i>Lentivirus </i></text>
<text top="670" left="55" width="241" height="9" font="font16" id="p1_t37" reading_order_no="43" segment_no="20" tag_type="text">bal number of HIV-positive patients is around 39.5 mil-</text>
<text top="682" left="55" width="241" height="9" font="font16" id="p1_t38" reading_order_no="44" segment_no="20" tag_type="text">lion as of December 2006. There was an estimated average</text>
<text top="694" left="55" width="241" height="9" font="font16" id="p1_t39" reading_order_no="45" segment_no="20" tag_type="text">of 2.9 million deaths and 4.3 million new cases in 2006<i>Retroviridae </i></text>
<text top="705" left="55" width="15" height="9" font="font16" id="p1_t40" reading_order_no="46" segment_no="20" tag_type="text">[8].</text>
<text top="506" left="313" width="219" height="9" font="font19" id="p1_t41" reading_order_no="47" segment_no="19" tag_type="title">Why consider gene therapy as a treatment modality?<a href="">2</a>]. HIV infection not only causes phys-</text>
<text top="517" left="313" width="241" height="9" font="font16" id="p1_t42" reading_order_no="48" segment_no="21" tag_type="text">Despite thousands of researchers worldwide working on a<a href="">3-</a></text>
<text top="529" left="313" width="241" height="9" font="font16" id="p1_t43" reading_order_no="49" segment_no="21" tag_type="text">cure for HIV infection, none of the modalities have been<a href="">7]. During th</a>e later stages of HIV infection, patients</text>
<text top="541" left="313" width="241" height="9" font="font16" id="p1_t44" reading_order_no="50" segment_no="21" tag_type="text">completely successful. Currently, four classes of anti-retro-</text>
<text top="553" left="313" width="241" height="9" font="font16" id="p1_t45" reading_order_no="51" segment_no="21" tag_type="text">viral drugs are available: nucleoside/nucleotide analogs,</text>
<text top="564" left="313" width="241" height="9" font="font16" id="p1_t46" reading_order_no="52" segment_no="21" tag_type="text">non-nucleoside reverse transcriptase inhibitors, protease</text>
<text top="576" left="313" width="241" height="9" font="font16" id="p1_t47" reading_order_no="53" segment_no="21" tag_type="text">inhibitors, and fusion (or entry) inhibitors. These drugs,</text>
<text top="588" left="313" width="241" height="9" font="font16" id="p1_t48" reading_order_no="54" segment_no="21" tag_type="text">used in various combinations to treat HIV, form what is</text>
<text top="599" left="313" width="241" height="9" font="font16" id="p1_t49" reading_order_no="55" segment_no="21" tag_type="text">known as highly active antiretroviral therapy (HAART).</text>
<text top="611" left="313" width="241" height="9" font="font16" id="p1_t50" reading_order_no="56" segment_no="21" tag_type="text">However, HAART is expensive, has high toxicity rates, and</text>
<text top="623" left="313" width="241" height="9" font="font16" id="p1_t51" reading_order_no="57" segment_no="21" tag_type="text">must be administered lifelong, i.e. it is not curative. In</text>
<text top="635" left="313" width="241" height="9" font="font16" id="p1_t52" reading_order_no="58" segment_no="21" tag_type="text">addition to the above problems, the rate of emergence of</text>
<text top="647" left="313" width="241" height="9" font="font16" id="p1_t53" reading_order_no="59" segment_no="21" tag_type="text">resistant strains is high post-HAART. In studies conducted</text>
<text top="658" left="313" width="241" height="9" font="font16" id="p1_t54" reading_order_no="60" segment_no="21" tag_type="text">in the United States and Europe, over 50% of patients</text>
<text top="670" left="313" width="241" height="9" font="font16" id="p1_t55" reading_order_no="61" segment_no="21" tag_type="text">experienced virologic failure (viremia) while on antiretro-<a href="">[8].</a></text>
<text top="682" left="313" width="241" height="9" font="font16" id="p1_t56" reading_order_no="62" segment_no="21" tag_type="text">viral therapy, and approximately 80% of these patients<i><b>Why consider gene therapy as a treatment modality?</b></i></text>
<text top="694" left="313" width="241" height="9" font="font16" id="p1_t57" reading_order_no="63" segment_no="21" tag_type="text">showed drug resistant HIV genotypes [9,10]. One long-</text>
<text top="705" left="313" width="241" height="9" font="font16" id="p1_t58" reading_order_no="64" segment_no="21" tag_type="text">term study found that by six years, approximately 80% of</text>
<text top="717" left="313" width="241" height="9" font="font16" id="p1_t59" reading_order_no="65" segment_no="21" tag_type="text">patients had their medications switched repeatedly due to</text>
<text top="729" left="313" width="241" height="9" font="font16" id="p1_t60" reading_order_no="66" segment_no="21" tag_type="text">drug resistance, resulting in an overall cumulative failure</text>
<text top="254" left="55" width="92" height="7" font="font20" id="p1_t61" reading_order_no="11" segment_no="9" tag_type="text">Published: 14 February 2007</text>
<text top="268" left="55" width="123" height="7" font="font21" id="p1_t62" reading_order_no="12" segment_no="12" tag_type="text">Genetic Vaccines and Therapy 2007, 5 :5</text>
<text top="268" left="187" width="88" height="7" font="font20" id="p1_t63" reading_order_no="13" segment_no="12" tag_type="text">doi:10.1186/1479-0556-5-5</text>
<text top="254" left="310" width="86" height="7" font="font20" id="p1_t64" reading_order_no="18" segment_no="10" tag_type="text">Received: 9 October 2006</text>
<text top="263" left="310" width="92" height="7" font="font20" id="p1_t65" reading_order_no="19" segment_no="11" tag_type="text">Accepted: 14 February 2007</text>
<text top="282" left="55" width="229" height="7" font="font20" id="p1_t66" reading_order_no="14" segment_no="13" tag_type="text">This article is available from: http://www.gvt-journal.com/content/5/1/5</text>
<text top="297" left="55" width="195" height="7" font="font20" id="p1_t67" reading_order_no="15" segment_no="14" tag_type="text">© 2007 Marathe and Wooley; licensee BioMed Central Ltd.</text>
<text top="306" left="55" width="492" height="7" font="font20" id="p1_t68" reading_order_no="16" segment_no="15" tag_type="text">This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),</text>
<text top="315" left="55" width="400" height="7" font="font20" id="p1_t69" reading_order_no="17" segment_no="15" tag_type="text">which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</text>
</page>
</pdf2xml>
